
Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

